ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2004
Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 16 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keyhole limpet hemocyanin (KLH) is an immune stimulant derived from a circulating glycoprotein of the marine mollusk Megathura crenulata. We previously reported that KLH inhibited the growth of human Barrett's-associated esophageal adenocarcinoma in vitro via apoptotic and nonapoptotic mechanisms. We hypothesize that KLH reduces the growth of Barrett's cancer cells by altering protein expression profiles. A cell line (SEG-1) derived from Barrett's-associated adenocarcinomas of the distal esophagus was selected. Cells were administered KLH (500 microg/ml) or vehicle. After 24 hours, cytosolic fractions were separated through two-dimensional gel electrophoresis. Statistical analysis was performed with Evolution Pro software to identify spots that were differentially expressed between the KLH and control groups. Proteins displaying a twofold or greater change in expression levels were selected for identification. In a total of 420 spots, 31 were differentially expressed between the KLH and control groups. In all, 12 were upregulated and 19 were downregulated. Of the 31, 17 were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proteomic evaluation shows downregulation of proteins associated with metabolic processes (glycolysis, protein synthesis). KLH also induced proteins indicative of oxidative stress (heat shock 70 family and UDP-glucose 6-dydrogenase). Our results indicate that growth arrest by KLH is accompanied by a cellular stress response and attenuation of metabolic processes. The use of KLH as adjuvant or topical therapy for Barrett's adenocarcinoma provides a promising development in the treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.